Mobidiag
Molecular diagnostics focusing on detection of infectious diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD1.2b (Public information from Apr 2021)
Company register number 1651007-2
Espoo Uusimaa (HQ)
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | 1.1m | 2.9m | 4.6m | 31.4m | 26.4m | 27.9m |
| % growth | 148 % | 141 % | 179 % | 56 % | 582 % | (16 %) | 6 % |
| EBITDA | (1.4m) | (2.9m) | (4.2m) | (8.6m) | 4.2m | <1m | (38.7m) |
| % EBITDA margin | (322 %) | (276 %) | (144 %) | (188 %) | 13 % | 3 % | (138 %) |
| Profit | (1.7m) | (3.6m) | (9.0m) | (14.5m) | (5.2m) | (20.1m) | (54.3m) |
| % profit margin | (390 %) | (337 %) | (306 %) | (315 %) | (17 %) | (76 %) | (194 %) |
| R&D budget | <1m | 1.0m | 3.0m | 5.0m | 40.0m | - | - |
| R&D % of revenue | 114 % | 95 % | 102 % | 109 % | 128 % | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
€15.0m | Debt | ||
| N/A | €1.2m | Early VC | |
* | €4.0m | Series A | |
* | €4.0m | Series B | |
€1.5m | Debt | ||
€10.0m | Series C | ||
* | €25.0m | Debt | |
$808m Valuation: $808m 23.4x EV/LTM Revenues 176.4x EV/LTM EBITDA | Acquisition | ||
| Total Funding | AUD32.6m | ||
Related Content
Recent News about Mobidiag
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.